Pluri and ZEO ScientifiX sign partnership, Pluri to take 50% stake in ZEO

Pluri Inc. (Nasdaq and TASE: PLUR) and ZEO ScientifiX, Inc. (OTCQB: ZEOX) announced on October 26, 2026 that they had entered into a definitive strategic agreement to expand the parties' U.S. manufacturing and commercialization platform serving the regenerative medicine, aesthetics, wellness, and longevity markets.¹

Under the deal, Pluri will grant ZEO defined rights to its manufacturing technology and related know-how associated with its regenerative medicine assets, while retaining ownership of its underlying technology and intellectual property.¹ In exchange, ZEO will initially issue shares of its common stock representing 50% of its issued and outstanding common stock immediately following closing.¹ The release also notes that the transaction and a contemplated additional share exchange will result in Pluri owning 50% of ZEO at closing following completion of the applicable transaction steps.¹

The agreement gives ZEO's commercial platform exclusive U.S. rights to Pluri's aesthetics line, since the Partnership Agreement provides for exclusive U.S. rights to Pluri's CellaV aesthetic product line, including future offerings, with CellaV being Pluri's wholly owned aesthetics subsidiary that develops cell-derived ingredients and aesthetic products.¹

Once the deal closes, ZEO's financial figures are expected to be folded into Pluri's books, as the companies state that ZEO's financial results are expected to be consolidated into Pluri's financial statements, subject to applicable accounting requirements.¹

The companies said closing is expected in the fourth quarter of 2026, subject to conditions including negotiation of ancillary agreements, certain approvals, and delivery of valuations, and that the transaction is not subject to stockholder approval by either company.¹